These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 25428177

  • 1. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC, Black M, Yoo J, Pinto N, Fernandes A, Haibe-Kains B, Boutros PC, Barrett JW.
    BMC Pharmacol Toxicol; 2014 Nov 27; 15():66. PubMed ID: 25428177
    [Abstract] [Full Text] [Related]

  • 2. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED, Hoshino D, Maldonado AT, Tyson DR, Weaver AM.
    JAMA Otolaryngol Head Neck Surg; 2015 Jun 27; 141(6):543-9. PubMed ID: 25855885
    [Abstract] [Full Text] [Related]

  • 3. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.
    Clin Cancer Res; 2016 Aug 01; 22(15):3884-93. PubMed ID: 26936917
    [Abstract] [Full Text] [Related]

  • 4. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
    Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A.
    Mol Cancer Ther; 2013 Oct 01; 12(10):1994-2005. PubMed ID: 23873848
    [Abstract] [Full Text] [Related]

  • 5. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J.
    Clin Cancer Res; 2016 Apr 15; 22(8):2009-19. PubMed ID: 26589432
    [Abstract] [Full Text] [Related]

  • 6. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.
    Clin Cancer Res; 2006 Jul 01; 12(13):4103-11. PubMed ID: 16818711
    [Abstract] [Full Text] [Related]

  • 7. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C, Contreras D, Navarro EM, Gutiérrez-Muñoz C, García-Escudero R, Paramio JM, Lorz C.
    Int J Mol Sci; 2018 Jun 21; 19(7):. PubMed ID: 29933569
    [Abstract] [Full Text] [Related]

  • 8. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.
    J Natl Cancer Inst; 2014 Sep 21; 106(9):. PubMed ID: 25099740
    [Abstract] [Full Text] [Related]

  • 9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.
    Cancer Lett; 2017 Apr 28; 392():71-82. PubMed ID: 28126323
    [Abstract] [Full Text] [Related]

  • 10. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
    Theurer JA, Stecho W, Yoo J, Kwan K, Wehrli B, Harry V, Black M, Pinto N, Winquist E, Palma D, Richter S, Barrett JW, Danielle MacNeil S, Fung K, Howlett CJ, Nichols AC.
    Pathol Oncol Res; 2016 Jan 28; 22(1):35-40. PubMed ID: 26271341
    [Abstract] [Full Text] [Related]

  • 11. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
    Al-Amri AM, Vatte C, Cyrus C, Chathoth S, Hashim TM, Mohamed YS, Al Ali R, Alsaid A, Al Ali A.
    Cancer Biomark; 2016 Jan 28; 16(3):377-83. PubMed ID: 26889984
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, Bruce JY, Wheeler DL, Kimple RJ.
    Mol Cancer Ther; 2017 Jul 28; 16(7):1257-1268. PubMed ID: 28446642
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.
    Clin Cancer Res; 2016 Jun 15; 22(12):2939-49. PubMed ID: 26763254
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N, Tsukuda M, Taguchi T, Nakazaki K, Sakakibara A, Takahashi H, Toth G, Nishimura G.
    Cancer Sci; 2011 Sep 15; 102(9):1717-23. PubMed ID: 21631644
    [Abstract] [Full Text] [Related]

  • 19. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
    Prasad A, Khudaynazar N, Tantravahi RV, Gillum AM, Hoffman BS.
    Oncotarget; 2016 Nov 29; 7(48):79388-79400. PubMed ID: 27764820
    [Abstract] [Full Text] [Related]

  • 20. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Goudot P, Bertolus C, Foray N, Kirova Y, Verrelle P, Saintigny P.
    BMC Med; 2017 Sep 01; 15(1):165. PubMed ID: 28859688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.